Physician profile

Carline Guerrier

Psychiatric/Mental Health (Nurse Practitioner) · Hempstead, NY

NPI 1841480852

$738.36

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$582.61

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $168.27 2023 Spravato
Neurocrine Biosciences, INC. $142.71 2022
Otsuka America Pharmaceutical, INC. $125.00 2024 Rexulti
Abbvie INC. $124.99 2024
Teva Pharmaceuticals USA, INC. $115.68 2024 Austedo Xr
Biogen, INC. $48.67 2023
Lundbeck LLC $13.04 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carline Guerrier

$738.36

in general payments reported 2019-2025

Years
2021-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/11172702/carline-guerrier

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.